Dana-Farber researchers present major cancer clinical trial results, including AI-driven data analysis, at ESMO Congress 2025.
Key Details
- 1Dana-Farber leads four phase 3 studies in breast, lung, and bladder cancer at ESMO Congress 2025.
- 2Key trials address advanced breast cancer treatment, NSCLC first-line therapy, and ctDNA-guided therapy in bladder cancer.
- 3Patient-reported data from SERENA-6 trial shows improved quality of life for metastatic breast cancer patients.
- 4Presentation of AI-generated synthetic cohorts from a 19,164 patient metastatic breast cancer dataset for real-world data analysis.
- 5Blood biomarker (KIM-1) study may help guide advanced kidney cancer treatment decisions.
- 6ESMO 2025 held in Berlin, Oct 17–21, with global participation.
Why It Matters
The use of AI to generate synthetic cohorts and analyze real-world oncology data can accelerate clinical trials and protect patient privacy, representing significant advancements for radiology, cancer informatics, and AI communities. These developments offer pathways to improved research collaboration and personalized cancer care.
Source
EurekAlert
Related News
•EurekAlert
Deep Learning Model Predicts Language Outcomes After Cochlear Implants Using MRI
AI model using deep transfer learning accurately predicts spoken language outcomes in deaf children after cochlear implantation based on pre-implantation brain MRI scans.
•EurekAlert
AI-Driven CT Tool Predicts Cancer Spread in Oropharyngeal Tumors
Researchers have created an AI tool that uses CT imaging to predict the spread risk of oropharyngeal cancer, offering improved treatment stratification.
•EurekAlert
AI Model PRTS Predicts Spatial Transcriptomics From H&E Histology Images
Researchers developed PRTS, a deep learning model that infers single-cell spatial transcriptomics from standard H&E-stained tissue images.